Answers are grounded in this paper and cite their sources.
Purpose: To evaluate frequency of clinically actionable drug-gene interactions and whether presence of genetic interactions was associated with time to medication discontinuation in a cohort of US Veterans with and without HIV. Methods: Pharmacogenomic interactions (PGx) were defined as Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A interactions. Using this definition, we identified 20 most frequently dispensed medications with at least one interaction as defined by CPIC. We calculated percentage of people dispensed ≥1 CPIC level A medication. Among those recipients, we calculated the percentage of people with a CPIC level A interaction (CPIC A PGx) and compared time to discontinuation between those with/without CPIC A PGx using Bonferroni corrected Wilcoxon rank-sum tests. Results: Of 1,452 patients, 70% were Black, 6% Hispanic, 22% White, and 3% other with the mean age at 56 years. Of these, 98% (1,420/1452) had at least one CPIC A medication, including antiretrovirals, and immunosuppressants. Of those who were dispensed with CPIC A medication, 83% had CPIC A PGx. The clinical recommendations for these interactions varied from dose to medication change. Among individuals prescribed efavirenz, having a PGx was associated with shorter time to discontinuation and Tacrolimus was associated with longer time to discontinuation. The remaining 18 CPIC medications did not demonstrate a significant association with time to discontinuation. Conclusion: Many patients with CPIC A PGx are prescribed CPIC medications. We found no clear pattern of shorter time to discontinuation for those with a CPIC A PGx. Future work should explore the real-world impact of specific interactions.
No takes yet. Share an insight, caveat, or question.
Kidwai‐Khan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: